Amgen Inc. $AMGN Shares Acquired by Warren Street Wealth Advisors LLC

Posted by Geri Gentry on Jun 22nd, 2026

Warren Street Wealth Advisors LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 390.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 20,715 shares of the medical research company’s stock after purchasing an additional 16,488 shares during the period. Amgen makes up 1.9% of Warren Street Wealth Advisors LLC’s portfolio, making the stock its 13th largest holding. Warren Street Wealth Advisors LLC’s holdings in Amgen were worth $7,289,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. High Note Wealth LLC raised its position in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after buying an additional 28 shares during the last quarter. TAGStone Capital Inc. lifted its stake in shares of Amgen by 0.7% in the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after acquiring an additional 28 shares during the period. Verus Capital Partners LLC boosted its holdings in shares of Amgen by 2.3% in the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after acquiring an additional 28 shares in the last quarter. Destination Wealth Management boosted its holdings in shares of Amgen by 2.1% in the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 29 shares in the last quarter. Finally, West Family Investments Inc. increased its stake in shares of Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after acquiring an additional 30 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on AMGN shares. Royal Bank Of Canada increased their price target on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a report on Thursday. Guggenheim dropped their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research report on Monday, May 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $350.00 target price on shares of Amgen in a research note on Wednesday, April 8th. Finally, Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average price target of $354.42.

Check Out Our Latest Analysis on AMGN

Amgen Stock Performance

Shares of AMGN opened at $337.60 on Monday. The company has a 50-day simple moving average of $340.71 and a 200-day simple moving average of $345.82. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company has a market capitalization of $182.21 billion, a PE ratio of 23.49, a P/E/G ratio of 3.39 and a beta of 0.42. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the previous year, the firm earned $4.90 earnings per share. The firm’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts predict that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Amgen Inc. $AMGN Shares Acquired by Warren Street Wealth Advisors LLC

Insider Activity

Analyst Upgrades and Downgrades

Amgen Stock Performance

About Amgen

Further Reading

You might be interested in: